Slide 1: Investor Presentation May 2025
INVESTOR PRESENTATION May 2025 Spółka notowana na Giełdzie Papierów Wartościowych w Warszawie
Slide 2: Legal disclaimers
Legal disclaimers This document has been prepared for informational purposes only, contains only summary information and is not intended to be exhaustive, nor is it intended to be the sole basis for any analysis or evaluation. Genomtec SA makes no representations (express or implied) re garding the
Slide 3: Agenda
AGENDA 1. ABOUT Genomtec 2. Current operational activities 3. Current project status oncoSNAAT 4. Clinical trials 5. Q&A session
Slide 4: An international team, a combination of science and business
An international team, a combination of science and business MANAGEMENT Miron Tokarski International team of 20 experts President of the Management Board, Co-founder of the Company Two locations: Wroclaw (PL) and Kent (UK) Co-creator of Genomtec technology and patents Doctor of Medical Sciences in t
Slide 5: An international team, a combination of science and business
An international team, a combination of science and business Genomtec SA is a medical technology company founded in late 2016 with the goal of commercializing ultrafast, mobile point-of-care genetic testing platforms through the development of proprietary optical systems and technologies.Streamlined
Slide 6: Genomtec Technology
GENOMTEC = Genomtec Technology
Slide 7: Genomtec SNAAT
Genomtec SNAAT Delivering innovative diagnostic technologies close to the patient – Point ofCare TEST SCOPE TESTING LOCATION Infections Clinics Doctor's offices Biomarkers Emergency Department Genetic variants Patient transportation Airports SNAAT technology (used, among others, in Genomtec ID visi
Slide 8: OncoSNAAT – use of Genomtec technology in oncology
OncoSNAAT– use of Genomtec technology in oncology Long waiting time for the Transporting samples Expensive analyzers Multi-step analytical High research costs >$400 result, even up to several extends the waiting time taking up a significant process requiring / test weeks for results and increases am
Slide 9: Development of OncoSNAAT project
Development of OncoSNAAT project
Slide 10: Project development OncoSNAAT - PARP funding of PLN 21.6 million
Project development OncoSNAAT- PARP funding of PLN 21.6 million 1000+ Laboratory reactions performed Development of an original method for diagnosing single-nucleotide changes cftDNA Selection of volumetric parameters of the sample Work on a DNA isolation method begins IP Two patent applications for
Slide 11: OncoSNAAT project milestones
OncoSNAAT project milestones A comprehensive approach enabling the diagnosis of common genetic variants that determine Methods for • Detection of multinucleotide genetic changes (patent the selection of appropriate therapy (CDx) in oncological treatment and in the future also in pending September 20
Slide 12: Scientific publication
Scientific publication scientific reports Explore content ¥ About the journal v Publish withus nature > scientificreports > articles > article Article | Onen access | Published 08 March 2025, Anew approach for the detection of genetic alterations utilizing modified loop-mediated isothermal amplifica
Slide 13: Current operational activities, M&A process status
Current operational activities, M&A process status
Slide 14: 2025 participation in leading business and scientific conferences
2025 participation in leading business and scientific conferences ESCMID Global 2025 (Austria) BIO 2025 (USA) (Planned) Association for Diagnostics & Laboratory Medicine 2025 (USA) (Planned Genomtec+Clairfield) AMP 2025 (USA) (Planned) So far, we have conducted dozens of meetings and presentations o
Slide 15: Changes in the organizational structure of the company in connection with the M&A process
Changes in the organizational structure of the company in connection with the M&A process CURRENTLY: GENOMTEC SA. Objective: • Adaptation to buyers' needs. One company implements all • Accelerate M&A transactions. projects • Increasing the value of the transaction. Status: ✓ An individual tax interp
Slide 16: POCT Genetic Testing Acquisitions Market
POCT Genetic Testing Acquisitions Market Genomtec capitalization = approx. $25m Value of acquisitions of majority IVD platforms comparable to Genomtec ID = > $100m INTELLECTUAL PROPERTY VALUATION 150 EUR 191.8 million gross Vivalytic • 14-year protection period for the entire IP portfolio Number of
Slide 17: M&A process status – synergy of business and R&D activities
M&A process status – synergy of business and R&D activities Dozens of meetings July 2023 - Present Building a list of interested parties Signing of NDAs Signing of confidentiality agreements with a number of interested entities. 5 areas of interest Exchange of data regarding technologies offered by
Slide 18: The state of the M&A process – technology
The state of the M&A process – technology Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity) ▪ A series of tests and optimizations of algorithms controlling the non- contact heating system were carried out in an extended range of outside tem
Slide 19: The state of the M&A process – technology
The state of the M&A process – technology Possibilities of accelerating diagnostics using Genomtec ID. ▪ In conjunction with the work focused on reducing the cost of producing the reaction card, at the request of one of the potential partners, the possibilities of using new reagents to shorten the t
Slide 20: Status of the M&A process – reduction of production costs
Status of the M&A process – reduction of production costs Costs of producing large-scale reaction cards. ▪ Discussions were held with a number of partners specializing in the production of lab-on-chip microfluidic systems. ▪ Two independent quotes were obtained (CDMO partners) related to scaling up
Slide 21: Corporate financial situation 2024 and share issue 1Q25
CORPORATE FINANCIAL SITUATION 2024 AND SHARE ISSUE 1Q25
Slide 22: Capital increase (February-March 2025)
Capital increase (February-March 2025) PLN 11 million ▪ Issue of 1,542,556 series P shares ▪ Participation of investors, including institutional ones, in the ABB process ▪ On March 12, the EGM decision confirming the transaction was made, registration in the National Court Register on March 19. SHAR
Slide 23: Summary
GENOMTEC = SUMMARY
Slide 24: Summary
Summary Innovative technology GMT ID's unique competitive position: cheap, Safe cash position 12 patents and over 30 patent applications have portable, rapid test for detecting 5 pathogens PLN 21.6 million of PARP subsidy – secures the been reported OncoSNAAT: Using the liquid biopsy technique - pro
Slide 25: Contact IR
Contact IR ccgroup investors@genomtec.com Agata Dzięciołowska Michal Wierzchowski https://genomtec.com/